Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357228 | 1.00 | EPHX1 (0.61) | EPHX1MAPTMAPK1MGLLACHE | |
| SCHEMBL16558025 | 1.00 | EPHX1 (0.61) | EPHX1MAPTMAPK1MGLLACHE | |
| SCHEMBL16449814 | 0.93 | EPHX1 (0.58) | EPHX1MAPTMAPK1MGLLACHE | |
| SCHEMBL9683638 | 0.93 | ACHE (0.55) | EPHX1MAPTMAPK1ACHE | |
| SCHEMBL16450795 | 0.91 | FAAH (0.56) | EPHX1MAPT | |
| SCHEMBL7745030 | 0.89 | PRKCA (0.54) | EPHX1ACHE | |
| SCHEMBL17790871 | 0.85 | MAPT (0.44) | EPHX1MAPTMAPK1ACHE | |
| SCHEMBL10832505 | 0.84 | ACHE (0.53) | EPHX1ACHE | |
| SCHEMBL16449807 | 0.84 | EPHX1 (0.47) | EPHX1MAPTMAPK1ACHE | |
| SCHEMBL12099412 | 0.83 | EPHX1 (0.58) | EPHX1MGLLACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9474916-B2 | Carbamates from glycerine carbonate for pearlization | EVONIK DEGUSSA GMBH (DE) | 2016-10-25 | — | — | US | claimed |
| US-20150044264-A1 | Carbamates from Glycerine Carbonate for Pearlization | EVONIK INDUSTRIES AG | 2015-02-12 | — | — | US | claimed |
| US-9474916-B2 | Carbamates from glycerine carbonate for pearlization | EVONIK DEGUSSA GMBH (DE) | 2016-10-25 | — | — | US | disclosed |
| US-9474916-B2 | Carbamates from glycerine carbonate for pearlization | EVONIK DEGUSSA GMBH (DE) | 2016-10-25 | — | — | US | disclosed |
| US-9474916-B2 | Carbamates from glycerine carbonate for pearlization | EVONIK DEGUSSA GMBH (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20150072856-A1 | ADJUVANTS BASED ON OPTIONALLY ALKOXYLATED REACTION PRODUCTS OF GLYCEROL CARBONATE AND ALKYLAMINES | BASF SE (DE) | 2015-03-12 | — | — | US | disclosed |
| US-20150072856-A1 | ADJUVANTS BASED ON OPTIONALLY ALKOXYLATED REACTION PRODUCTS OF GLYCEROL CARBONATE AND ALKYLAMINES | BASF SE (DE) | 2015-03-12 | — | — | US | disclosed |
| US-20150044264-A1 | Carbamates from Glycerine Carbonate for Pearlization | EVONIK INDUSTRIES AG | 2015-02-12 | — | — | US | disclosed |
| US-20150044264-A1 | Carbamates from Glycerine Carbonate for Pearlization | EVONIK INDUSTRIES AG | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072856-A1 | ADJUVANTS BASED ON OPTIONALLY ALKOXYLATED REACTION PRODUCTS OF GLYCEROL CARBONATE AND ALKYLAMINES | GK, PHOSPHO1, AGPAT5 | EPHX1 624/4885MAPT 3494/4885MAPK1 1434/4885 |
| US-20150044264-A1 | Carbamates from Glycerine Carbonate for Pearlization | SGMS2, SGMS1, PHOSPHO1 | EPHX1 3424/4885MAPT 4112/4885MAPK1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.